Lymphoma

The phase 3 EPCORE FL-1 trial showed that adding Epkinly to Rituxan and Revlimid delivered superior PFS and response rates.

Among older patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), Epkinly plus R-mini-CHOP appeared to be well tolerated and elicited responses.

Among patients with previously untreated diffuse large B-cell lymphoma, odronextamab has been associated with early efficacy.

I believe time to be a gift, and as such, my sister was gifted more than a decade despite a terminal illness, and I do have gratitude for that.

Facing my cancer diagnosis, I learned it’s okay not to be okay and found comfort in laughter, honesty, and the support of loved ones.

The FDA approved Breyanzi for adults with relapsed or refractory marginal zone lymphoma who received at least two prior lines of systemic therapy.

The U.S. commercial launch of LYMPHIR offers a new treatment option for patients with relapsed/refractory stage 1 to 3 cutaneous T-cell lymphoma.

The FDA granted traditional approval to Jaypirca for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

The FDA has approved Epkinly plus Revlimid and Rituxan for the treatment of patients with relapsed or refractory follicular lymphoma.

I want to appreciate and acknowledge the one person who has had a profoundly positive impact on me throughout my 16-year journey with chronic small lymphocytic lymphoma.

MB-105 received a special FDA status to help deliver faster treatment options for people with relapsed T-cell lymphoma who have few options.

A cancer survivor explains how humor helped her during her cancer journey.

I share how walking has helped me through lymphoma, knee surgeries and treatments, and why staying active keeps me physically, mentally and spiritually strong.

Stage 2 lymphoma is treatable. Diagnosis and treatment depend on subtype, but most patients achieve excellent outcomes with modern therapies.

Even after all these years with small lymphocytic lymphoma, I’ve accepted that the scares will never completely go away — but neither will my resilience.

Lymphoma survivors with chronic fatigue participating in a multidisciplinary intervention program experienced benefits to fatigue and quality of life.

The FDA granted breakthrough therapy designation to sonrotoclax for adults with relapsed or refractory mantle cell lymphoma, based on phase 1/2 data.

Lymphoma is a treatable cancer of the immune system; early diagnosis and personalized treatment with chemo and radiation often lead to a cure.

For patients with relapsed/refractory mantle cell lymphoma Lunsumio plus Polivy was associated with durable responses.

The FDA approved Monjuvi with Revlimid and Rituxan for follicular lymphoma, the same combination that brought survivor Troy Anderson a lasting response.

Autumn lifts my spirit, reminding me to embrace beauty, family, faith, and gratitude even while living with cancer.

ctDNA-MRD testing better predicted outcomes versus PET/CT scans for large B-cell lymphoma, leading to NCCN guideline updates for remission assessment.

Writing and reading help me stay grounded and find meaning while living with chronic cancer, balancing health, family and speaking out against hatred.

The FDA accepted a supplemental application for Breyanzi to treat adults with relapsed or refractory marginal zone lymphoma after two prior therapies.

When treatment ended, people expected relief, but what I felt was loss, fear, and the weight of a life forever changed.